CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential
- 27 November 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 155 (2) , 249-256
Abstract
Summary: Cellular adjuvants such as dendritic cells (DC) are in the focus of tumour immunotherapy. In DC-vaccine trials, induction of tumour antigen-specific immunity is observed frequently and well-documented clinical responses have been reported. However, the overall response rate is less than 3%, therefore alternative strategies are being investigated. CD40-activated B cells (CD40-B) have been characterized previously as an interesting alternative because they present antigen efficiently and can be expanded by several logs from small amounts of peripheral blood. To determine the central technical challenges of cell-based vaccines we performed a single-patient analysis of 502 patients from DC-based tumour vaccine trials and identified at least three factors contributing to their limited efficiency: (1) lack of cell numbers; (2) lack of documented purity thus high contamination of bystander cells; and (3) lack of quality control and thus heterogeneous or unknown expression of important surface molecules such as major histocompatibility complex (MHC) and chemokine receptors. Based on these findings we re-evaluated the CD40-B approach in cancer patients. Here, we show that proliferation of B cells from cancer patients is equivalent to that observed in healthy donors. Purity is always > 90% after 2 weeks and remains stable for several weeks. They have comparable antigen-presenting capability determined phenotypically and by allogeneic mixed lymphocyte reaction. Expression of CCR7 and CD62L was detected in all samples and B cells migrated towards the relevant homing chemokines. Taken together, CD40-B cells from cancer patients can be expanded in virtually unlimited numbers at high purity and full function concerning antigen-presentation and migratory properties.Keywords
This publication has 56 references indexed in Scilit:
- RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphomaGene Therapy, 2008
- Conditional Immortalization of Human B Cells by CD40 LigationPLOS ONE, 2008
- Preliminary Analysis of Patients With Progressive Renal Cell Carcinoma Vaccinated With CA9-peptide–Pulsed Mature Dendritic CellsJournal of Immunotherapy, 2007
- Immortalization of Epstein–Barr virus‐negative human B lymphocytes with minimal chromosomal instabilityPathology International, 2006
- CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvantsBlood, 2006
- Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor MicroenvironmentClinical Cancer Research, 2006
- Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T‐cell immunity in vivoImmunology, 2005
- In vitro Induction of Myeloid Leukemia–Specific CD4 and CD8 T Cells by CD40 Ligand – Activated B Cells Gene Modified to Express Primary Granule ProteinsClinical Cancer Research, 2005
- B‐Lymphocytes Activated by CD40 Ligand Induce an Antigen‐Specific Anti‐Tumour Immune Response by Direct and Indirect Activation of CD8+ T‐cellsScandinavian Journal of Immunology, 2004
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996